# LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy

> **NCT04166604** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **GERCOR - Multidisciplinary Oncology Cooperative Group** · enrollment: 176 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Trifluridine/Tipiracil

## Key facts

- **NCT ID:** NCT04166604
- **Lead sponsor:** GERCOR - Multidisciplinary Oncology Cooperative Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-05-20
- **Primary completion:** 2023-11-10
- **Final completion:** 2025-11
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04166604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04166604, "LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04166604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*